NEW YORK (360Dx) – Sydney, Australia-based SpeeDx said this week that the US Food and Drug Administration has granted Breakthrough Device designation for its ResistancePlus GC molecular test, which could expedite its path toward regulatory clearance. ResistancePlus GC provides ciprofloxacin susceptibility and resistance information to effectively guide treatment for N. gonorrhea, the firm said. The test detects both N. gonorrhea and sequences in the gyrA gene of the bacteria associated with susceptibility or resistance to ciprofloxacin, an antibiotic used to treat sexually transmitted infections.
Abbott Park, Illinois-based Abbott this week declared a quarterly dividend of $.32 per share, payable Aug. 15 to shareholders of record at the close of business on July 15.
In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on 360Dx.